Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry
The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS). We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Reg...
Gespeichert in:
| Veröffentlicht in: | Modern rheumatology 2024-03, Vol.34 (3), p.584-591 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 591 |
|---|---|
| container_issue | 3 |
| container_start_page | 584 |
| container_title | Modern rheumatology |
| container_volume | 34 |
| creator | Karakaş, Ali Gulle, Semih Can, Gerçek Dalkılıc, Ediz Akar, Servet Koca, Suleyman Serdar Pehlivan, Yavuz Senel, Soner Tufan, Abdurrahman Ozturk, Mehmet Akif Yilmaz, Sema Yazici, Ayten Cefle, Ayse Yüce İnel, Tuba Erez, Yesim Sari, Ismail Birlik, Merih Direskeneli, Haner Akkoc, Nurullah Onen, Fatos |
| description | The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS).
We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI) .05).
This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients. |
| doi_str_mv | 10.1093/mr/road061 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2829425850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2829425850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c287t-1845fe13b3da8f5d5f0ec61bcd356d5c765f0b98529ebe4c3e513a1648a3c37b3</originalsourceid><addsrcrecordid>eNo9kM9O3DAQhy1U1OVPLzxA5WNVKcWO48Q-VYWWgkBCWi3nyLHHW5ck3nocpLxBH4Nn4clYxMJpRvP75nf4CDnh7BtnWpwO6TRF41jN98gBr4QumprpD2-71HJBDhH_MiakVvojWYhGVIpJcUD-_4yANHaAIc_UeA8205zA5AHGTBPgJo4INEeKYKf7ME6D6agZ3dMjTukhPJiehvHp0Yz3cx8xjGv68uLmPuSA3-kSTF_0wQN1JhvqUxxo_gN0dbe8Pru63ebrgDnNx2Tfmx7h024ekbuLX6vzy-Lm9vfV-Y-bwpaqyQVXlfTARSecUV466RnYmnfWCVk7aZt6e-m0kqWGDiorQHJheF0pI6xoOnFEvrz2blL8NwHmdghooe_NCHHCtlSlrkqpJNuiX19RmyJiAt9uUhhMmlvO2hfz7ZDanfkt_HnXO3UDuHf0TbV4BuZMhGs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2829425850</pqid></control><display><type>article</type><title>Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><creator>Karakaş, Ali ; Gulle, Semih ; Can, Gerçek ; Dalkılıc, Ediz ; Akar, Servet ; Koca, Suleyman Serdar ; Pehlivan, Yavuz ; Senel, Soner ; Tufan, Abdurrahman ; Ozturk, Mehmet Akif ; Yilmaz, Sema ; Yazici, Ayten ; Cefle, Ayse ; Yüce İnel, Tuba ; Erez, Yesim ; Sari, Ismail ; Birlik, Merih ; Direskeneli, Haner ; Akkoc, Nurullah ; Onen, Fatos</creator><creatorcontrib>Karakaş, Ali ; Gulle, Semih ; Can, Gerçek ; Dalkılıc, Ediz ; Akar, Servet ; Koca, Suleyman Serdar ; Pehlivan, Yavuz ; Senel, Soner ; Tufan, Abdurrahman ; Ozturk, Mehmet Akif ; Yilmaz, Sema ; Yazici, Ayten ; Cefle, Ayse ; Yüce İnel, Tuba ; Erez, Yesim ; Sari, Ismail ; Birlik, Merih ; Direskeneli, Haner ; Akkoc, Nurullah ; Onen, Fatos</creatorcontrib><description>The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS).
We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI) < 25 kg/m2], overweight (BMI: 25-30 kg/m2), and obese (BMI ≥ 30 kg/m2). Disease activity was evaluated at baseline, 3, 6, and 12 months. Drug retention rates at 12 months were also investigated.
There were 166 AS patients using secukinumab (56.6% male, mean age: 44.9 ± 11.6 years). The median follow-up time was 17.2 (3-33.2) months. Forty-eight (28.9%) patients were obese. The mean age was higher in the obese group than in others (P = .003). There was no statistically significant difference in Bath Ankylosing Spondylitis Disease Activity Index 50, Assessment of SpondyloArthritis international Society 20 (ASAS20), ASAS40, Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity, and ASDAS clinically important improvement responses between the three groups at 3, 6, and 12 months, although they were numerically lower in obese patients. Drug retention rates at 12 months were similar in all groups (P > .05).
This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients.</description><identifier>ISSN: 1439-7595</identifier><identifier>EISSN: 1439-7609</identifier><identifier>DOI: 10.1093/mr/road061</identifier><identifier>PMID: 37348053</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Female ; Humans ; Male ; Middle Aged ; Obesity - complications ; Spondylitis, Ankylosing - complications ; Spondylitis, Ankylosing - drug therapy ; Treatment Outcome</subject><ispartof>Modern rheumatology, 2024-03, Vol.34 (3), p.584-591</ispartof><rights>Japan College of Rheumatology 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c287t-1845fe13b3da8f5d5f0ec61bcd356d5c765f0b98529ebe4c3e513a1648a3c37b3</citedby><cites>FETCH-LOGICAL-c287t-1845fe13b3da8f5d5f0ec61bcd356d5c765f0b98529ebe4c3e513a1648a3c37b3</cites><orcidid>0000-0002-4667-0603 ; 0000-0001-7737-4180 ; 0000-0001-9026-9641</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37348053$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karakaş, Ali</creatorcontrib><creatorcontrib>Gulle, Semih</creatorcontrib><creatorcontrib>Can, Gerçek</creatorcontrib><creatorcontrib>Dalkılıc, Ediz</creatorcontrib><creatorcontrib>Akar, Servet</creatorcontrib><creatorcontrib>Koca, Suleyman Serdar</creatorcontrib><creatorcontrib>Pehlivan, Yavuz</creatorcontrib><creatorcontrib>Senel, Soner</creatorcontrib><creatorcontrib>Tufan, Abdurrahman</creatorcontrib><creatorcontrib>Ozturk, Mehmet Akif</creatorcontrib><creatorcontrib>Yilmaz, Sema</creatorcontrib><creatorcontrib>Yazici, Ayten</creatorcontrib><creatorcontrib>Cefle, Ayse</creatorcontrib><creatorcontrib>Yüce İnel, Tuba</creatorcontrib><creatorcontrib>Erez, Yesim</creatorcontrib><creatorcontrib>Sari, Ismail</creatorcontrib><creatorcontrib>Birlik, Merih</creatorcontrib><creatorcontrib>Direskeneli, Haner</creatorcontrib><creatorcontrib>Akkoc, Nurullah</creatorcontrib><creatorcontrib>Onen, Fatos</creatorcontrib><title>Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry</title><title>Modern rheumatology</title><addtitle>Mod Rheumatol</addtitle><description>The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS).
We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI) < 25 kg/m2], overweight (BMI: 25-30 kg/m2), and obese (BMI ≥ 30 kg/m2). Disease activity was evaluated at baseline, 3, 6, and 12 months. Drug retention rates at 12 months were also investigated.
There were 166 AS patients using secukinumab (56.6% male, mean age: 44.9 ± 11.6 years). The median follow-up time was 17.2 (3-33.2) months. Forty-eight (28.9%) patients were obese. The mean age was higher in the obese group than in others (P = .003). There was no statistically significant difference in Bath Ankylosing Spondylitis Disease Activity Index 50, Assessment of SpondyloArthritis international Society 20 (ASAS20), ASAS40, Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity, and ASDAS clinically important improvement responses between the three groups at 3, 6, and 12 months, although they were numerically lower in obese patients. Drug retention rates at 12 months were similar in all groups (P > .05).
This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients.</description><subject>Adult</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Obesity - complications</subject><subject>Spondylitis, Ankylosing - complications</subject><subject>Spondylitis, Ankylosing - drug therapy</subject><subject>Treatment Outcome</subject><issn>1439-7595</issn><issn>1439-7609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM9O3DAQhy1U1OVPLzxA5WNVKcWO48Q-VYWWgkBCWi3nyLHHW5ck3nocpLxBH4Nn4clYxMJpRvP75nf4CDnh7BtnWpwO6TRF41jN98gBr4QumprpD2-71HJBDhH_MiakVvojWYhGVIpJcUD-_4yANHaAIc_UeA8205zA5AHGTBPgJo4INEeKYKf7ME6D6agZ3dMjTukhPJiehvHp0Yz3cx8xjGv68uLmPuSA3-kSTF_0wQN1JhvqUxxo_gN0dbe8Pru63ebrgDnNx2Tfmx7h024ekbuLX6vzy-Lm9vfV-Y-bwpaqyQVXlfTARSecUV466RnYmnfWCVk7aZt6e-m0kqWGDiorQHJheF0pI6xoOnFEvrz2blL8NwHmdghooe_NCHHCtlSlrkqpJNuiX19RmyJiAt9uUhhMmlvO2hfz7ZDanfkt_HnXO3UDuHf0TbV4BuZMhGs</recordid><startdate>20240328</startdate><enddate>20240328</enddate><creator>Karakaş, Ali</creator><creator>Gulle, Semih</creator><creator>Can, Gerçek</creator><creator>Dalkılıc, Ediz</creator><creator>Akar, Servet</creator><creator>Koca, Suleyman Serdar</creator><creator>Pehlivan, Yavuz</creator><creator>Senel, Soner</creator><creator>Tufan, Abdurrahman</creator><creator>Ozturk, Mehmet Akif</creator><creator>Yilmaz, Sema</creator><creator>Yazici, Ayten</creator><creator>Cefle, Ayse</creator><creator>Yüce İnel, Tuba</creator><creator>Erez, Yesim</creator><creator>Sari, Ismail</creator><creator>Birlik, Merih</creator><creator>Direskeneli, Haner</creator><creator>Akkoc, Nurullah</creator><creator>Onen, Fatos</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4667-0603</orcidid><orcidid>https://orcid.org/0000-0001-7737-4180</orcidid><orcidid>https://orcid.org/0000-0001-9026-9641</orcidid></search><sort><creationdate>20240328</creationdate><title>Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry</title><author>Karakaş, Ali ; Gulle, Semih ; Can, Gerçek ; Dalkılıc, Ediz ; Akar, Servet ; Koca, Suleyman Serdar ; Pehlivan, Yavuz ; Senel, Soner ; Tufan, Abdurrahman ; Ozturk, Mehmet Akif ; Yilmaz, Sema ; Yazici, Ayten ; Cefle, Ayse ; Yüce İnel, Tuba ; Erez, Yesim ; Sari, Ismail ; Birlik, Merih ; Direskeneli, Haner ; Akkoc, Nurullah ; Onen, Fatos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c287t-1845fe13b3da8f5d5f0ec61bcd356d5c765f0b98529ebe4c3e513a1648a3c37b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Obesity - complications</topic><topic>Spondylitis, Ankylosing - complications</topic><topic>Spondylitis, Ankylosing - drug therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karakaş, Ali</creatorcontrib><creatorcontrib>Gulle, Semih</creatorcontrib><creatorcontrib>Can, Gerçek</creatorcontrib><creatorcontrib>Dalkılıc, Ediz</creatorcontrib><creatorcontrib>Akar, Servet</creatorcontrib><creatorcontrib>Koca, Suleyman Serdar</creatorcontrib><creatorcontrib>Pehlivan, Yavuz</creatorcontrib><creatorcontrib>Senel, Soner</creatorcontrib><creatorcontrib>Tufan, Abdurrahman</creatorcontrib><creatorcontrib>Ozturk, Mehmet Akif</creatorcontrib><creatorcontrib>Yilmaz, Sema</creatorcontrib><creatorcontrib>Yazici, Ayten</creatorcontrib><creatorcontrib>Cefle, Ayse</creatorcontrib><creatorcontrib>Yüce İnel, Tuba</creatorcontrib><creatorcontrib>Erez, Yesim</creatorcontrib><creatorcontrib>Sari, Ismail</creatorcontrib><creatorcontrib>Birlik, Merih</creatorcontrib><creatorcontrib>Direskeneli, Haner</creatorcontrib><creatorcontrib>Akkoc, Nurullah</creatorcontrib><creatorcontrib>Onen, Fatos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Modern rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karakaş, Ali</au><au>Gulle, Semih</au><au>Can, Gerçek</au><au>Dalkılıc, Ediz</au><au>Akar, Servet</au><au>Koca, Suleyman Serdar</au><au>Pehlivan, Yavuz</au><au>Senel, Soner</au><au>Tufan, Abdurrahman</au><au>Ozturk, Mehmet Akif</au><au>Yilmaz, Sema</au><au>Yazici, Ayten</au><au>Cefle, Ayse</au><au>Yüce İnel, Tuba</au><au>Erez, Yesim</au><au>Sari, Ismail</au><au>Birlik, Merih</au><au>Direskeneli, Haner</au><au>Akkoc, Nurullah</au><au>Onen, Fatos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry</atitle><jtitle>Modern rheumatology</jtitle><addtitle>Mod Rheumatol</addtitle><date>2024-03-28</date><risdate>2024</risdate><volume>34</volume><issue>3</issue><spage>584</spage><epage>591</epage><pages>584-591</pages><issn>1439-7595</issn><eissn>1439-7609</eissn><abstract>The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS).
We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI) < 25 kg/m2], overweight (BMI: 25-30 kg/m2), and obese (BMI ≥ 30 kg/m2). Disease activity was evaluated at baseline, 3, 6, and 12 months. Drug retention rates at 12 months were also investigated.
There were 166 AS patients using secukinumab (56.6% male, mean age: 44.9 ± 11.6 years). The median follow-up time was 17.2 (3-33.2) months. Forty-eight (28.9%) patients were obese. The mean age was higher in the obese group than in others (P = .003). There was no statistically significant difference in Bath Ankylosing Spondylitis Disease Activity Index 50, Assessment of SpondyloArthritis international Society 20 (ASAS20), ASAS40, Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity, and ASDAS clinically important improvement responses between the three groups at 3, 6, and 12 months, although they were numerically lower in obese patients. Drug retention rates at 12 months were similar in all groups (P > .05).
This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients.</abstract><cop>England</cop><pmid>37348053</pmid><doi>10.1093/mr/road061</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-4667-0603</orcidid><orcidid>https://orcid.org/0000-0001-7737-4180</orcidid><orcidid>https://orcid.org/0000-0001-9026-9641</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1439-7595 |
| ispartof | Modern rheumatology, 2024-03, Vol.34 (3), p.584-591 |
| issn | 1439-7595 1439-7609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2829425850 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE |
| subjects | Adult Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Female Humans Male Middle Aged Obesity - complications Spondylitis, Ankylosing - complications Spondylitis, Ankylosing - drug therapy Treatment Outcome |
| title | Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T03%3A28%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20obesity%20affect%20treatment%20response%20to%20secukinumab%20and%C2%A0survival%20in%C2%A0ankylosing%20spondylitis?%20Real-life%20data%20from%20the%20TURKBIO%20Registry&rft.jtitle=Modern%20rheumatology&rft.au=Karaka%C5%9F,%20Ali&rft.date=2024-03-28&rft.volume=34&rft.issue=3&rft.spage=584&rft.epage=591&rft.pages=584-591&rft.issn=1439-7595&rft.eissn=1439-7609&rft_id=info:doi/10.1093/mr/road061&rft_dat=%3Cproquest_cross%3E2829425850%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2829425850&rft_id=info:pmid/37348053&rfr_iscdi=true |